Story thread · 3 reports / 3 sources
Novartis stock surged after its oral multiple sclerosis pill passed two late-stage trials
qz.com · 12d
How the coverage leans
Across 3 sources · syndicated copies counted once
The oral drug remibrutinib cut relapse rates in patients with relapsing multiple sclerosis, beating a rival treatment in both studies
First report: Novartis' Rhapsido safer than rivals, Phase 3 multiple sclerosis data suggest — endpts.com, 13d
The coverage
- STAT+: Novartis gets multiple sclerosis win with BTK inhibitor
statnews.com · 13d
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.